Harbin Pharmaceutical Group (600664.SH): Protein succinate iron oral solution has obtained drug registration certificate.

16:02 02/02/2026

Haiyao Group (600664.SH) announced recently that its subsidiary, Haiyao Group Chinese Medicine Factory (referred to as "Chinese Medicine Factory"), has received the "Drug Registration Certificate" for protein succinate iron oral solution from the National Medical Products Administration, with the certificate number 2026S00300. This product has been approved for registration.

Harbin Pharmaceutical Group (600664.SH) announced that its subsidiary company, Harbin Pharmaceutical Group Traditional Chinese Medicine Factory (referred to as "TCM Factory"), has received the Drug Registration Certificate for the Oral Solution of Protein Succinylate Iron from the National Medical Products Administration [Number: 2026S00300]. The product has been approved for registration. The Oral Solution of Protein Succinylate Iron is an over-the-counter medication used for the treatment of iron deficiency anemia, including that caused by insufficient iron intake or absorption, chronic blood loss, and iron deficiency anemia due to pregnancy and lactation.

Increasing presence in the US market: Astrazeneca PLC Sponsored ADR (AZN.US) listing on the New York Stock Exchange, London position may be weakened.

SHUN WO GROUP (01591) issued 133 million shares under the "3-for-1" benchmark distribution.

Shaanxi Panlong Pharmaceutical (002864.SZ): Fluibuprofen patch approved for clinical trials.

Increasing presence in the US market: Astrazeneca PLC Sponsored ADR (AZN.US) listing on the New York Stock Exchange, London position may be weakened.

SHUN WO GROUP (01591) issued 133 million shares under the "3-for-1" benchmark distribution.

Shaanxi Panlong Pharmaceutical (002864.SZ): Fluibuprofen patch approved for clinical trials.